European drugs regulator starts rolling review of Sinovac anti-coronavirus jab
Europe's medicines regulator has confirmed it has started a real-time review of Sinovac's (SVA.O) Covid-19 vaccine.
Data on the jab - Covid-19 Vaccine (Vero Cell) Inactivated - will be assessed as they are made available to help European government's give the all-clear for its use.
This is the first Chinese vaccine the EMA is studying in real-time, and the fourth Covid-19 vaccine under such a review, including those from CureVac , Novavax Inc (NVAX.O) and Russia's Sputnik V.
The vaccine contains inactivated or dead versions of the SARS-CoV-2 virus to help the human body's immune system make antibodies.
Last month, Sinovac said its third production plant for its vaccine, branded CoronaVac in some regions, was ready and would double its annual capacity to 2 billion doses.
The firm said more than 200 million doses of Sinovac's vaccine have been delivered globally.
Daily newsletterReceive essential international news every morningSubscribe